Cough News and Research

RSS

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

H1N1 virus causes more life-threatening complications than seasonal flu

Infection with the H1N1 virus, or swine flu, causes more life-threatening complications than seasonal flu in children with sickle cell disease, according to research from Johns Hopkins Children's Center.

8 Dec 2009

First Edition: December 7, 2009

President Obama took to the Hill this weekend to boost Senate Democrats' health reform efforts. Meanwhile, the negotiations on flashpoint issues such as the public option continue.

7 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

CDC announces the start of National Influenza Vaccination Week

Today the Centers for Disease Control and Prevention (CDC) announced the start of National Influenza Vaccination Week. While the week was designed to highlight the importance of flu vaccinations, it also brings to light the importance of taking additional steps to keep you and your family healthy during the peak cold and flu season of December, January and beyond.

7 Dec 2009

Updated results from phase III EXTEND clinical trial of pixantrone released

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

7 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

Measles deaths decline worldwide by 78%, experts warn against complacency

Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.

4 Dec 2009

Study shows herbal medicine is effective for treating acute rhinosinusitis

Rhinosinusitis is an inflammatory process involving one or more of the paranasal sinuses that typically follows a viral upper respiratory tract infection (RTI). The term ‘acute rhinosinusitis’ is used instead of ‘acute sinusitis’ because it is the currently internationally accepted terminology.

4 Dec 2009

New study suggests e-cigarettes can help alleviate nicotine cravings and improve general health

A groundbreaking new survey into the electronic cigarette, smokers' health and smoking cessation, carried out by NJOY retailers E Cigarette Direct and analysed by tobacco harm reduction scientists, has shown encouraging results.

3 Dec 2009

Lung disease linked to the use of contaminated well water in a CPAP machine

Many people rely on continuous positive airway pressure (CPAP) machines as a safe and effective treatment for sleep apnea. But a new case report describes a rare complication—a lingering inflammatory disease of the lungs, apparently related to the use of contaminated well water in a CPAP machine. The report appears in the December Southern Medical Journal, official journal of the Southern Medical Association.

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Tianyin Pharmaceutical Co., Inc.,, a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

1 Dec 2009

Study examines role of low-oxygen exposure in heart failure patients

Distance runners who live at high altitudes with low oxygen levels are known to improve their performance during races in areas that are at sea level. Can heart failure patients, who suffer from fatigue, improve their exercise performance by staying in a tent-like, high-altitude simulator?

1 Dec 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Cough News and Research

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Amgen announces results from first Phase 1/2 study of Nplate

H1N1 virus causes more life-threatening complications than seasonal flu

First Edition: December 7, 2009

Native Remedies selects TransMedia Group as its PR firm

CDC announces the start of National Influenza Vaccination Week

Updated results from phase III EXTEND clinical trial of pixantrone released

VELCADE based regimens are cost-effective for payers and patients, finds study

Measles deaths decline worldwide by 78%, experts warn against complacency

Study shows herbal medicine is effective for treating acute rhinosinusitis

New study suggests e-cigarettes can help alleviate nicotine cravings and improve general health

Lung disease linked to the use of contaminated well water in a CPAP machine

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Study examines role of low-oxygen exposure in heart failure patients

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News